Radioligand-binding assay reveals distinct autoantibody preferences for type I interferons in APS I and myasthenia gravis subgroups

Journal of Clinical Immunology

Volumn 32, Issue 2, 2012, Pages 230-237

  Hapnes, Liv ^a   Willcox, Nick ^b   Oftedal, Bergithe E V ^a,c   Owe, Jone F ^a,c   Gilhus, Nils Erik ^a,c   Meager, Anthony ^d   Husebye, Eystein S ^a,c   Wolff, Anette S Bøe ^a  

^a UNIVERSITY OF BERGEN   (Norway)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

AIRE; APECED; Autoimmune polyendocrine syndrome type I; Autoimmunity; Late Onset MG; Myasthenia gravis; Thymoma; Type I interferons

Indexed keywords

ALPHA2 INTERFERON; ALPHA8 INTERFERON; AUTOANTIBODY; INTERFERON; NEUTRALIZING ANTIBODY; OMEGA INTERFERON; UNCLASSIFIED DRUG;

ADDISON DISEASE; ADULT; AGED; ANTIBODY DETECTION; ARTICLE; AUTOIMMUNE POLYENDOCRINOPATHY; CONTROLLED STUDY; DIAGNOSTIC VALUE; HUMAN; MAJOR CLINICAL STUDY; MYASTHENIA GRAVIS; PRIORITY JOURNAL; RADIOASSAY; RADIOLIGAND BINDING ASSAY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; THYMOMA; VIRUS NEUTRALIZATION; AGE; BLOOD; EPIDEMIOLOGY; FEMALE; IMMUNOLOGY; MALE;

AGE FACTORS; AUTOANTIBODIES; FEMALE; HUMANS; INTERFERON TYPE I; MALE; MYASTHENIA GRAVIS; POLYENDOCRINOPATHIES, AUTOIMMUNE; RADIOLIGAND ASSAY; SEROEPIDEMIOLOGIC STUDIES; THYMOMA; THYMUS NEOPLASMS;

EID: 84863631532     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-011-9617-4     Document Type: Article

References (37)

1. The Finnish German APECEDConsorttium. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHDtype zinc-finger domains. Autoimmune polyendocrinopathycandidiasis- ectodermal dystrophy. Nat Genet. 1997;17:399-403.
2. Nagamine K, Peterson P, Scott HS, Kudoh J, Minoshima S, Heino M, et al. Positional cloning of the APECED gene. Nat Genet. 1997;17:393-8. (Pubitemid 27518386)
3. Anderson MS, Venanzi ES, Klein L, Chen Z, Berzins SP, Turley SJ, et al. Projection of an immunological self shadow within the thymus by the aire protein. Science. 2002;298:1395-401. (Pubitemid 35346134)
4. Kekalainen E, Tuovinen H, Joensuu J, Gylling M, Franssila R, Pontynen N, et al. A defect of regulatory T cells in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J Immunol. 2007;178:1208-15. (Pubitemid 46095195)
5. Husebye ES, Perheentupa J, Rautemaa R, Kampe O. Clinical manifestations and management of patients with autoimmune polyendocrine syndrome type I. J Intern Med. 2009;265:514-29.
6. Meager A, Visvalingam K, Peterson P, Moll K, Murumagi A, Krohn K, et al. Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1. PLoS Med. 2006;3:e289.
7. Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev. 2004;202:8-32. (Pubitemid 39576902)
8. Soderbergh A, Myhre AG, Ekwall O, Gebre-Medhin G, Hedstrand H, Landgren E, et al. Prevalence and clinical associations of 10 defined autoantibodies in autoimmune polyendocrine syndrome type I. J Clin Endocrinol Metab. 2004;89:557-62. (Pubitemid 38269857)
9. Kisand K, Boe Wolff AS, Podkrajsek KT, Tserel L, Link M, Kisand KV, et al. Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17- associated cytokines. J Exp Med. 2010;207(2):299-308.
10. Puel A, Doffinger R, Natividad A, Chrabieh M, Barcenas-Morales G, Picard C, et al. Autoantibodies against IL-17A, IL-17F, and IL- 22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J Exp Med. 2010;207(2):291-7.
11. Wolff AS, Erichsen MM, Meager A, Magitta NF, Myhre AG, Bollerslev J, et al. Autoimmune polyendocrine syndrome type 1 in Norway: phenotypic variation, autoantibodies, and novel mutations in the autoimmune regulator gene. J Clin Endocrinol Metab. 2007;92:595-603.
12. Fitzgerald-Bocarsly P, Feng D. The role of type I interferon production by dendritic cells in host defense. Biochimie. 2007;89:843-55. (Pubitemid 47001647)
13. Kisand K, Link M, Wolff AS, Meager A, Tserel L, Org T, et al. Interferon autoantibodies associated with AIRE deficiency decrease the expression of IFN-stimulated genes. Blood. 2008;112:2657-66.
14. Meager A, Wadhwa M, Dilger P, Bird C, Thorpe R, Newsom- Davis J, et al. Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferonalpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis. Clin Exp Immunol. 2003;132:128-36. (Pubitemid 36418915)
15. Shiono H, Wong YL, Matthews I, Liu JL, Zhang W, Sims G, et al. Spontaneous production of anti-IFN-alpha and anti-IL-12 autoantibodies by thymoma cells from myasthenia gravis patients suggests autoimmunization in the tumor. Int Immunol. 2003;15:903-13. (Pubitemid 36987288)
16. Strobel P, Murumagi A, Klein R, Luster M, Lahti M, Krohn K, et al. Deficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendocrinopathy syndrome type 1 (APS-1). J Pathol. 2007;211:563-71. (Pubitemid 46502433)
17. Feltkamp TE, van den Berg-Loonen PM, Nijenhuis LE, Engelfriet CP, van Rossum AL, van Loghem JJ, et al. Myasthenia gravis, autoantibodies, and HL-A antigens. Br Med J. 1974;1:131-3.
18. Meloni A, Furcas M, Cetani F, Marcocci C, Falorni A, Perniola R, et al. Autoantibodies against type I interferons as an additional diagnostic criterion for autoimmune polyendocrine syndrome type I. J Clin Endocrinol Metab. 2008;93:4389-97. (Pubitemid 352789536)
19. Oftedal BE, Boe Wolff AS, Bratland E, Kampe O, Perheentupa J, Myhre AG, et al. Radioimmunoassay for autoantibodies against interferon omega; its use in the diagnosis of autoimmune polyendocrine syndrome type I. Clin Immunol. 2008;129 (1):163-9.
20. Alimohammadi M, Bjorklund P, Hallgren A, Pontynen N, Szinnai G, Shikama N, et al. Autoimmune polyendocrine syndrome type 1 and NALP5, a parathyroid autoantigen. N Engl J Med. 2008;358:1018-28. (Pubitemid 351347101)
21. Buckley C, Newsom-Davis J, Willcox N, Vincent A. Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence? Neurology. 2001;57:1579-82. (Pubitemid 33055473)
22. Meager A, Peterson P, Willcox N. Hypothetical review: thymic aberrations and type-I interferons; attempts to deduce autoimmunizing mechanisms from unexpected clues in monogenic and paraneoplastic syndromes. Clin Exp Immunol. 2008;154:141-51.
23. Olanow CW, Lane RJ, Roses AD. Thymectomy in late-onset myasthenia gravis. Arch Neurol. 1982;39:82-3. (Pubitemid 12222024)
24. Kisand K, Lilic D, Casanova JL, Peterson P, Meager A, Willcox N. Mucocutaneous candidiasis and autoimmunity against cytokines in APECED and thymoma patients: clinical and pathogenetic implications. Eur J Immunol. 2011;41:1517-27.
25. Schluep M, Willcox N, Ritter MA, Newsom-Davis J, Larche M, Brown AN. Myasthenia gravis thymus: clinical, histological and culture correlations. J Autoimmun. 1988;1:445-67.
26. Tackenberg B, Schlegel K, Happel M, Eienbroker C, Gellert K, Oertel WH, et al. Expanded TCR Vbeta subsets of CD8(+) T-cells in late-onset myasthenia gravis: novel parallels with thymoma patients. J Neuroimmunol. 2009;216:85-91.
27. Aarli JA, Romi F, Skeie GO, Gilhus NE. Myasthenia gravis in individuals over 40. Ann N Y Acad Sci. 2003;998:424-31. (Pubitemid 37194194)
28. Compston DA, Vincent A, Newsom-Davis J, Batchelor JR. Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain. 1980;103:579-601. (Pubitemid 10001182)
29. Alpert LI, Papatestas A, Kark A, Osserman RS, Osserman K. A histologic reappraisal of the thymus in myasthenia gravis. A correlative study of thymic pathology and response to thymectomy. Arch Pathol. 1971;91:55-61.
30. Strobel P, Moritz R, Leite MI, Willcox N, Chuang WY, Gold R, et al. The ageing and myasthenic thymus: a morphometric study validating a standard procedure in the histological workup of thymic specimens. J Neuroimmunol. 2008;201-202:64-73.
31. Matsui N, Nakane S, Nakagawa Y, Kondo K, Mitsui T, Matsumoto T, et al. Increasing incidence of elderly onset patients with myasthenia gravis in a local area of Japan. J Neurol Neurosurg Psychiatry. 2009;80:1168-71.
32. Somnier FE. Increasing incidence of late-onset anti-AChR antibody-seropositive myasthenia gravis. Neurology. 2005;65:928-30. (Pubitemid 41362144)
33. Skeie GO, Aarli JA, Gilhus NE. Titin and ryanodine receptor antibodies in myasthenia gravis. Acta Neurol Scand Suppl. 2006;183:19-23.
34. Kazarian M, Calbo J, Proost N, Carpenter CL, Berns A, Laird-Offringa IA. Immune response in lung cancer mouse model mimics human anti-Hu reactivity. J Neuroimmunol. 2009;217:38-45.
35. Miller RA. The aging immune system: primer and prospectus. Science. 1996;273:70-4. (Pubitemid 26255423)
36. Rosato E, Salsano F. Immunity, autoimmunity and autoimmune diseases in older people. J Biol Regul Homeost Agents. 2008;22:217-24.
37. Rowley MJ, Buchanan H, Mackay IR. Reciprocal change with age in antibody to extrinsic and intrinsic antigens. Lancet. 1968;2:24-6.